SCHEMBL6400977

SCHEMBL6400977

COC(=O)c1[nH]c2ccc([N+](C)(C)C)cc2c1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.41
ALDH1A1 P00352 8/20 0.41
GAA P10253 6/20 0.41
MAPT P10636 5/20 0.41
HPGD P15428 4/20 0.41
HSD17B10 Q99714 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
TUBB4A P04350 7/20 0.41
TUBB P07437 7/20 0.41
TUBA3C P0DPH7 7/20 0.41
TUBA1B P68363 7/20 0.41
TUBA4A P68366 7/20 0.41
TUBB4B P68371 7/20 0.41
TUBB3 Q13509 7/20 0.41
TUBB2A Q13885 7/20 0.41
TUBB8 Q3ZCM7 7/20 0.41
TUBA3E Q6PEY2 7/20 0.41
TUBA1A Q71U36 7/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6331518 0.89 KDM4E (0.47) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL27385781 0.84 GABRA1 (0.44) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL2735787 0.81 KMT2A (0.55) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL3338049 0.77 MEN1 (0.58) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL829225 0.71 MEN1 (0.45) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL21474560 0.71 ALDH1A1 (0.50) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL6330885 0.70 GAA (0.40) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL13925978 0.70 GABRA1 (0.47) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL386770 0.69 KDM4E (0.41) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL2351650 0.69 GABRA1 (0.60) KDM4EALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032860-A1 CBI analogs of CC-1065 and the duocarmycins THE SCRIPPS RESEARCH INSTITUTE (US) 2005-02-10 US disclosed
US-20040002528-A1 CBI analogs of CC-1065 and the duocarmycins THE SCRIPPS RESEARCH INSTITUTE (US) 2004-01-01 US disclosed
US-6548530-B1 Antitumor drugs incorporate the 1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one (CBI) alkylation subunit; cytotoxic activity THE SCRIPPS RESEARCH INSTITUTE 2003-04-15 US disclosed
EP-0862553-A4 CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS SCRIPPS RESEARCH INST (US) 1999-02-03 EP disclosed
EP-0862553-A1 CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS The Scripps Research Institute (US) 1998-09-09 EP disclosed
WO-1997012862-A1 CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS THE SCRIPPS RESEARCH INSTITUTE (US) 1997-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002528-A1 CBI analogs of CC-1065 and the duocarmycins DBI, DCK, CCNI KDM4E 721/4885ALDH1A1 3378/4885GAA 2484/4885
US-20050032860-A1 CBI analogs of CC-1065 and the duocarmycins DBI, CCNI, DCK KDM4E 479/4885ALDH1A1 2716/4885GAA 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.